GenoSplice and the Curie Institute join their forces to propose a global service on biological data analysis in Oncology. Press release (in French) is available by clicking here.
This study published in Nature Structural & Molecular Biology was done in collaboration with University of Cambridge, Tel-Aviv University and Affymetrix. Position-dependent alternative splicing activity revealed by global profiling of alternative splicing events regulated by PTB. Article: “Position-dependent alternative splicing activity revealed by global profiling of alternative splicing events regulated Read more…
Caroline Hego performs the experimental work of GenoSplice, in particular microarray experiments.
ILSI-Biomed 2010 follows the success of previous annual conferences: last year’s event drew 6,000 industry players, engineers and scientists, with 800 participants from 35 countries and in excess of 2,500 one-on-one meetings.
We applied our EASANA® platform to analyze the effect of estrogen treatments on the gene expression regulation at the exon level on a breast cancer cell line (collaboration with INSERM and the Curie Institute). Article: “Estrogen regulation and physiopathologic significance of alternative promoters in breast cancer.” Dutertre M, Gratadou L, Read more…
This press release (in French) is available on the Ouest-France website or directly for download in PDF format.
“GenoSplice annonce de nouvelles pistes menant à l’identification de biomarqueurs pronostiques dans le cancer du sein à partir d’évènements d’épissage” You can acces this press release in french in pdf format.
Frédéric Lemoine will participate in the developments of GenoSplice, in particular regarding the analysis of high-throughput sequencing data.
We applied our EASANA® platform to analyze the splicing factor expression and transcriptome among 11 normal human tissues using the Affymetrix Exon Arrays (collaboration with INSERM). Article “Splicing factor and exon profiling across human tissues.” de la Grange P, Gratadou L, Delord M, Dutertre M, Auboeuf D. Nucleic Acids Res. Read more…
We applied our EASANA® platform to identify regulated exons between mammary gland primary tumors with different metastatic property. Expression of the subsequent validated splicing variants was then correlated with prognosis of breast cancer patients through restrospective study (collaboration with INSERM, CNRS and the Curie Institute). Article “Exon-based clustering of murine Read more…